Could a single cell treatment free liver transplant patients from lifelong drugs?

NCT ID NCT05234190

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a personalized cell therapy called QEL-001 in 33 liver transplant recipients. The therapy uses a patient's own cells, modified to train the immune system to accept the donated liver. The goal is to see if it is safe and allows patients to stop taking anti-rejection medications without their body rejecting the liver.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder liver failure Rejection, Psychology transplant rejection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, CB2 0QQ, United Kingdom

  • G. Gergorio Maranon

    Madrid, Spain

  • H. Clinic Barcelona

    Barcelona, Spain

  • H. Saint Luc

    Brussels, Belgium

  • Hopital Erasme

    Brussels, Belgium

  • Hospital Reina Sofia

    Córdoba, Spain

  • King's College Hospital NHS Foundation Trust

    London, SE5 9RS, United Kingdom

  • Queen Elizabeth Hospital

    Birmingham, United Kingdom

  • Royal Free London NHS Foundation Trust

    London, NW3 2QG, United Kingdom

  • UZ Leuven

    Leuven, 3000, Belgium